Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- An Overview of Drug Discovery and Development
-
78 min
1. Rules and filters and their impact on success in chemical biology and drug discovery- Dr. Christopher Lipinski
-
37 min
2. Where did drugs come from?- Dr. David Swinney
- Target Selection in Early Stage Drug Discovery
-
42 min
3. G-Protein coupled receptors in drug discovery- Dr. Mark Wigglesworth
-
42 min
4. Enzymology in drug discovery 1- Prof. Robert Copeland
-
66 min
5. Enzymology in drug discovery 2- Prof. Robert Copeland
-
41 min
6. Inhibiting protein-protein interactions 1- Dr. Adrian Whitty
-
35 min
7. Inhibiting protein-protein interactions 2- Dr. Adrian Whitty
- Key Drug Discovery Challenges in Major Therapeutic Areas
-
64 min
8. Current trends in antiviral drug development- Prof. Dr. Erik De Clercq
-
27 min
9. The challenge of developing drugs for neglected parasitic diseases- Prof. James Mckerrow
-
55 min
10. Is there a role for academia in drug discovery- Dr. Adrian J. Ivinson
-
31 min
11. Key drug discovery challenges in cardiovascular medicine- Dr. Dan Swerdlow
- Dr. Michael V. Holmes
- Methods of Hit Identification
-
46 min
12. Fragment-based lead discovery- Dr. Daniel A. Erlanson
- Medicinal Chemistry and SAR
-
53 min
13. Hit to lead- Dr. Michael Rafferty
-
37 min
14. Prodrug strategies to overcome problems in drug therapy- Prof. Jarkko Rautio
-
40 min
15. Deep ocean microorganisms yield mechanistically-novel anticancer agents- Prof. William Fenical
- From Lead to Drug
-
25 min
16. Biomarkers in drug development: potential use and challenges- Dr. Abdel-Bassett Halim
- Case Studies in Drug Discovery
-
35 min
17. Current concepts for the management of patients with osteoporosis- Dr. Michael Lewiecki
-
35 min
-
36 min
19. Teixobactin kills pathogens without detectable resistance- Prof. Kim Lewis
-
20 min
20. Discovery of schizophrenia drug targets from DISC1 mechanisms- Prof. Atsushi Kamiya
- Archived Lectures *These may not cover the latest advances in the field
-
46 min
21. CNS-drug design- Prof. Quentin Smith
-
38 min
22. Imatinib as a paradigm of targeted cancer therapies- Prof. Brian Druker
-
44 min
23. New and emerging treatments for osteoporosis- Dr. Michael Lewiecki
-
38 min
24. Prodrugs and drug delivery- Prof. Jarkko Rautio
Printable Handouts
Navigable Slide Index
- Introduction
- Introduction - ten commandments
- IDU
- TFT
- Methisazone
- Amantadine
- Ribavirin
- Ara-A
- HIV
- Replicative cycle of HIV
- Suramin
- Zidovudine
- Emtricitabine
- TDF
- Drug interrelations and combination
- Truvada
- Atripla
- Complera
- Quad (stribild)
- GS-7340
- Quad (planned)
- Another planned quad
- Cobicistat & Ritonavir
- HCV
- HCV genome and potential targets
- Available HCV drugs
- Telaprevir
- Boceprevir
- Asunaprevir
- GS-9256
- GS-9451
- Danoprevir
- Vaniprevir
- Narlaprevir
- Simeprevir
- Drugs which target NS5A
- Daclatasvir
- Drugs that target NS5B (nucleoside)
- Sofosbuvir
- Mericitabine
- Drugs that target NS5B (non-nucleoside)
- VX-222
- BI 201335
- Tegobuvir
- Setrobuvir
- Filibuvir
- VCH-916 & VCH-759
- Drugs that target cellular enzymes
- Alisporivir
- The principle for the future treatment of HCV
- Phase II DAA-based combination clinical trials
- HSV
- Acyclovir
- Valaciclovir
- Penciclovir & Famciclovir
- HSV DNA synthesis
- AIC316
- VZV
- BVDU
- Degradation of BVDU to BVU
- Cf 1743 & FV-100
- ASP2151
- HCMV
- Ganciclovir & Valganciclovir
- Phosphonoformic acid: Foscarnet
- HPMPC
- Maribavir
- Letermovir
- Poxviruses
- Post-exposure treatments for monkeypox virus
- HDP-cidofovir
- ST-246
- HBV
- Anti-HBV agents
- Lamivudine
- Adefovir dipivoxil
- Entecavir
- Telbivudine
- Viread
- CHB virologic response
- Influenza virus
- Antiviral influenza replication inhibition
- Zanamivir
- Oseltamivir (tamiflu)
- Tamiflu packaging
- RWJ-270201: Peramivir
- Laninamivir octanoate
- Favipiravir
- Favipiravir mechanism
- Enveloped viruses
- Neplanocin A
- dUY11
- LJ-001
- FGI-106
- Picornaviruses
- Pleconaril
- Pirodavir
- Rupintrivir
- TBZE-029
- City hall
- Rega institute building
- Henri Joseph Rega
- Mentor
- Seed of wisdom
Topics Covered
- Chemotherapy of virus infections, AIDS, and malignant diseases
- Molecular mechanism of action & enzyme targets of antiviral and antitumor agents
- Nucleoside and nucleotide analogues
- Reverse transcriptase inhibitors
- Virus adsorption, fusion and uncoating inhibitors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
De Clercq, E. (2013, September 23). Current trends in antiviral drug development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/LHVX4583.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dr. Erik De Clercq has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Current trends in antiviral drug development
Published on September 23, 2013
64 min
